NEXPLANON

Nexplanon Adverse Events Reported to the FDA Over Time

How are Nexplanon adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Nexplanon, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Nexplanon is flagged as the suspect drug causing the adverse event.

Most Common Nexplanon Adverse Events Reported to the FDA

What are the most common Nexplanon adverse events reported to the FDA?

Pregnancy With Implant Contraceptiv...	59 (7.31%)
No Adverse Event	54 (6.69%)
Medical Device Complication	49 (6.07%)
Abortion Spontaneous	36 (4.46%)
Device Breakage	22 (2.73%)
Drug Interaction	14 (1.73%)
Implant Site Pain	14 (1.73%)
Product Quality Issue	14 (1.73%)
Maternal Drugs Affecting Foetus	11 (1.36%)
Implant Site Pruritus	10 (1.24%)
Abortion Missed	9 (1.12%)
	Show More
Complication Of Device Insertion	9 (1.12%)
Convulsion	9 (1.12%)
Epilepsy	9 (1.12%)
Abortion Induced	8 (.99%)
Contusion	8 (.99%)
Death Neonatal	8 (.99%)
Headache	8 (.99%)
Hypersensitivity	8 (.99%)
Implant Site Reaction	8 (.99%)
Menorrhagia	8 (.99%)
Metrorrhagia	8 (.99%)
Device Dislocation	7 (.87%)
Erythema	7 (.87%)
Premature Baby	7 (.87%)
Dizziness	6 (.74%)
Drug Ineffective	6 (.74%)
Amenorrhoea	5 (.62%)
Condition Aggravated	5 (.62%)
Implant Site Erythema	5 (.62%)
Implant Site Swelling	5 (.62%)
Nausea	5 (.62%)
Pain In Extremity	5 (.62%)
Pruritus	5 (.62%)
Unintended Pregnancy	5 (.62%)
Urticaria	5 (.62%)
Vision Blurred	5 (.62%)
Aggression	4 (.5%)
Cerebral Infarction	4 (.5%)
Deep Vein Thrombosis	4 (.5%)
Depression	4 (.5%)
Dyspnoea	4 (.5%)
Erysipelas	4 (.5%)
Excessive Granulation Tissue	4 (.5%)
Fibromyalgia	4 (.5%)
Implant Site Cellulitis	4 (.5%)
Implant Site Infection	4 (.5%)
Infection	4 (.5%)
Laceration	4 (.5%)
Muscle Spasms	4 (.5%)
Off Label Use	4 (.5%)
Paraesthesia	4 (.5%)
Pyrexia	4 (.5%)
Swelling	4 (.5%)
Vaginal Haemorrhage	4 (.5%)
Vomiting	4 (.5%)
Abdominal Pain	3 (.37%)
Abortion	3 (.37%)
Angioedema	3 (.37%)
Constipation	3 (.37%)
Device Failure	3 (.37%)
Discomfort	3 (.37%)
Eczema	3 (.37%)
Feeling Abnormal	3 (.37%)
Hypoaesthesia	3 (.37%)
Implant Site Cyst	3 (.37%)
Implant Site Haematoma	3 (.37%)
Influenza Like Illness	3 (.37%)
Injury	3 (.37%)
Lip Swelling	3 (.37%)
Local Swelling	3 (.37%)
Malaise	3 (.37%)
Oxygen Saturation Decreased	3 (.37%)
Palpitations	3 (.37%)
Post Procedural Complication	3 (.37%)
Pregnancy With Contraceptive Device	3 (.37%)
Procedural Complication	3 (.37%)
Procedural Pain	3 (.37%)
Staphylococcal Infection	3 (.37%)
Treatment Noncompliance	3 (.37%)
Weight Increased	3 (.37%)
Abdominal Distension	2 (.25%)
Adverse Event	2 (.25%)
Alopecia	2 (.25%)
Anxiety	2 (.25%)
Aplastic Anaemia	2 (.25%)
Blindness Congenital	2 (.25%)
Bronchitis	2 (.25%)
Cellulitis	2 (.25%)
Cholestasis	2 (.25%)
Complication Of Device Removal	2 (.25%)
Death	2 (.25%)
Drug Hypersensitivity	2 (.25%)
Endometritis	2 (.25%)
Fallopian Tube Cyst	2 (.25%)
Fatigue	2 (.25%)
Flushing	2 (.25%)
Food Poisoning	2 (.25%)
Haematoma	2 (.25%)
Hypercoagulation	2 (.25%)
Hypoglycaemia	2 (.25%)

Share/Embed Graph Export Data

This graph shows the top adverse events submitted to the FDA for Nexplanon, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Nexplanon is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Nexplanon

What are the most common Nexplanon adverse events reported to the FDA?

Procedural And Device Related Injur...	102 (12.64%)
Pregnancy, Labour, Delivery And Pos...	69 (8.55%)
Administration Site Reactions	60 (7.43%)
Abortions And Stillbirth	49 (6.07%)
Epidermal And Dermal Conditions	26 (3.22%)
Therapeutic And Nontherapeutic Effe...	24 (2.97%)
Menstrual Cycle And Uterine Bleedin...	23 (2.85%)
Neurological	21 (2.6%)
Injuries	20 (2.48%)
Infections - Pathogen Unspecified	18 (2.23%)
Seizures	18 (2.23%)
	Show More
Gastrointestinal Signs	16 (1.98%)
Product Quality Issues	15 (1.86%)
Bacterial Infectious	14 (1.73%)
Allergic Conditions	11 (1.36%)
Chemical Injury And Poisoning	11 (1.36%)
Fatal Outcomes	10 (1.24%)
Musculoskeletal And Connective Tiss...	9 (1.12%)
Obstetric And Gynecological Therape...	9 (1.12%)
Angiedema And Urticaria	8 (.99%)
Headaches	8 (.99%)
Muscle	8 (.99%)
Neonatal And Perinatal Conditions	7 (.87%)
Embolism And Thrombosis	6 (.74%)
Gastrointestinal Motility And Defec...	6 (.74%)
Lifestyle Issues	6 (.74%)
Ovarian And Fallopian Tube	6 (.74%)
Depressed Mood Disorders	5 (.62%)
Medication Errors	5 (.62%)
Movement Disorders	5 (.62%)
Physical Examination Topics	5 (.62%)
Therapeutic Procedures And Supporti...	5 (.62%)
Vision	5 (.62%)
Anxiety Disorders	4 (.5%)
Body Temperature Conditions	4 (.5%)
Central Nervous System Vascular	4 (.5%)
Glucose Metabolism Disorders	4 (.5%)
Personality Disorders	4 (.5%)
Respiratory	4 (.5%)
Skin And Subcutaneous Tissue	4 (.5%)
Vulvovaginal Disorders	4 (.5%)
Appetite And General Nutritional	3 (.37%)
Cardiac Disorder Signs	3 (.37%)
Hepatic And Hepatobiliary	3 (.37%)
Increased Intracranial Pressure And...	3 (.37%)
Metabolic, Nutritional And Blood Ga...	3 (.37%)
Oral Soft Tissue Conditions	3 (.37%)
Placental, Amniotic And Cavity Diso...	3 (.37%)
Schizophrenia And Other Psychotic	3 (.37%)
Skin Appendage Conditions	3 (.37%)
Vascular	3 (.37%)
Vascular Hemorrhagic	3 (.37%)
Anemias Nonhemolytic And Marrow Dep...	2 (.25%)
Bone And Joint Therapeutic Procedur...	2 (.25%)
Cardiac Arrhythmias	2 (.25%)
Coagulopathies And Bleeding Diathes...	2 (.25%)
Electrolyte And Fluid Balance Condi...	2 (.25%)
Eye Disorders Congenital	2 (.25%)
Gastrointestinal Conditions	2 (.25%)
Lower Respiratory Tract Disorders	2 (.25%)
Peripheral Neuropathies	2 (.25%)
Renal Disorders	2 (.25%)
Reproductive Neoplasms Female Malig...	2 (.25%)
Tissue	2 (.25%)
Aneurysms And Artery Dissections	1 (.12%)
Connective Tissue Disorders	1 (.12%)
Coronary Artery	1 (.12%)
Cutaneous Neoplasms Benign	1 (.12%)
Economic And Housing Issues	1 (.12%)
Endocrine Investigations	1 (.12%)
Exocrine Pancreas Conditions	1 (.12%)
Family Issues	1 (.12%)
Fungal Infectious	1 (.12%)
Maternal Complications Of Labour An...	1 (.12%)
Mood Disorders	1 (.12%)
Nephropathies	1 (.12%)
Psychiatric	1 (.12%)
Renal And Urinary Tract Disorders C...	1 (.12%)
Sexual Dysfunctions, Disturbances A...	1 (.12%)
Sleep Disorders	1 (.12%)
Suicidal And Self-injurious Behavio...	1 (.12%)
Upper Respiratory Tract Disorders	1 (.12%)
Vascular Inflammations	1 (.12%)
Viral Infectious	1 (.12%)

Share/Embed Graph Export Data

This graph shows the top categories of adverse events submitted to the FDA for Nexplanon, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Nexplanon is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.